Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Dupilumab for prurigo nodularis: Case series and review of the literature

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Certolizumab pegol for hidradenitis suppurativa: Case report and literature review

    Research output: Contribution to journalLetterResearchpeer-review

  2. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature

    Research output: Contribution to journalReviewResearchpeer-review

  4. Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Reduction in actinic keratoses following 9-valent human papilloma virus vaccination

    Research output: Contribution to journalLetterResearchpeer-review

  1. Airway hyperresponsiveness to inhaled mannitol identifies a cluster of non-eosinophilic asthma patients with high symptom burden

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Wearing Occlusive Gloves Increases the Density of Staphylococcus aureus in Patients with Hand Eczema

    Research output: Contribution to journalJournal articleResearch

View graph of relations

Dupilumab is a recombinant complete human monoclonal antibody modulating the signaling of interleukin-4 and interleukin-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis. Here, we present three cases of prurigo nodularis treated off-label with dupilumab, and a review of the existing literature. All patients in this study had longstanding severe disease and had tried multiple treatment modalities. They were treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. Systematic literature searches were performed to identify literature describing the evaluation of the effect of treatment with dupilumab in prurigo nodularis. The physician's assessment of the patients revealed a good or excellent response to the treatment with dupilumab. Patients were evaluated after treatment for 4 and 7 months. Treatment was generally well-tolerated; one in three patients reported dry eyes. Four studies with a total of 11 patients (range: 1-4) were identified by the literature search. Complete response was noted in all 11 patients. Treatment with dupilumab appears to be safe and well-tolerated with clinical benefit in recalcitrant prurigo nodularis. Larger randomized and controlled trials using validated outcome measures are needed before dupilumab could be applied in clinical settings.

Original languageEnglish
Article numbere13222
JournalDermatologic Therapy
Volume33
Issue number2
Pages (from-to)e13222
ISSN1396-0296
DOIs
Publication statusPublished - Mar 2020

    Research areas

  • anti-IL-4, biologics, dupilumab, prurigo nodularis

ID: 61699785